Trgovina Kymera Therapeutics, Inc. - KYMR CFD
Dodaj med priljubljene- Povzetek
- Zgodovinski podatki
- Dogodki
- Izkaz poslovnega izida
- Bilanca stanja
- Denarni tok
- Lastništvo
Pogoji trgovanja
| Razmik | 0.10 | ||||||||
|
Nočna pristojbina za nakup
Long position overnight fee
Pojdi na platformo | -0.024068% | ||||||||
|
Nočna pristojbina za prodajo
Short position overnight fee
Pojdi na platformo | 0.001846% | ||||||||
| Čas nočne pristojbine | 21:00 (UTC) | ||||||||
| Min. tržena količina | 1 | ||||||||
| Valuta | USD | ||||||||
| Kritje | 20% | ||||||||
| Borza | United States of America | ||||||||
| Provizija na trgovanje | 0% |
*Information provided by Capital.com
Ključni statistični podatki
| Predhodno. Zapri* | 28.73 |
| Odpri* | 28.48 |
| Enoletna sprememba* | -29.37% |
| Dnevni razpon* | 28.08 - 29.2 |
| Razpon 52 wk | 13.15-44.75 |
| Povprečni obseg (10 dni) | 409.05K |
| Povprečni obseg (3 meseci) | 10.71M |
| Tržna kapitalizacija | 1.62B |
| Razmerje P/E | -100.00K |
| Število delnic v obtoku | 55.18M |
| Prihodki | 46.83M |
| EPS | -2.88 |
| Dividenda (donosnost v %) | N/A |
| Beta | -100.00K |
| Datum naslednjega zaslužka | May 1, 2023 |
Vse podatke je zagotovil Refinitiv, razen podatkov, označenih z zvezdico, ki so *podatki, ki jih je zagotovil Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Zapiranje | Change | Change (%) | Odpiranje | High | Low |
|---|---|---|---|---|---|---|
| Mar 28, 2023 | 28.08 | -0.60 | -2.09% | 28.68 | 29.22 | 28.07 |
| Mar 27, 2023 | 28.73 | 0.00 | 0.00% | 28.73 | 29.73 | 28.42 |
| Mar 24, 2023 | 29.30 | 0.88 | 3.10% | 28.42 | 29.57 | 28.03 |
| Mar 23, 2023 | 28.81 | 0.33 | 1.16% | 28.48 | 29.50 | 27.81 |
| Mar 22, 2023 | 28.05 | -1.67 | -5.62% | 29.72 | 30.03 | 28.03 |
| Mar 21, 2023 | 30.00 | -0.08 | -0.27% | 30.08 | 31.03 | 29.91 |
| Mar 20, 2023 | 30.71 | 0.74 | 2.47% | 29.97 | 31.00 | 29.76 |
| Mar 17, 2023 | 30.98 | 0.89 | 2.96% | 30.09 | 31.25 | 29.60 |
| Mar 16, 2023 | 31.01 | 0.35 | 1.14% | 30.66 | 31.59 | 29.77 |
| Mar 15, 2023 | 31.10 | 0.26 | 0.84% | 30.84 | 31.52 | 29.93 |
| Mar 14, 2023 | 31.57 | -0.59 | -1.83% | 32.16 | 33.08 | 30.85 |
| Mar 13, 2023 | 31.15 | 2.50 | 8.73% | 28.65 | 31.37 | 28.65 |
| Mar 10, 2023 | 29.56 | -1.41 | -4.55% | 30.97 | 31.26 | 28.44 |
| Mar 9, 2023 | 31.66 | -0.36 | -1.12% | 32.02 | 33.39 | 31.30 |
| Mar 8, 2023 | 33.10 | 1.08 | 3.37% | 32.02 | 33.15 | 32.02 |
| Mar 7, 2023 | 32.85 | 0.33 | 1.01% | 32.52 | 33.66 | 32.11 |
| Mar 6, 2023 | 32.58 | 0.11 | 0.34% | 32.47 | 32.85 | 31.47 |
| Mar 3, 2023 | 32.76 | 0.21 | 0.65% | 32.55 | 32.90 | 31.88 |
| Mar 2, 2023 | 32.41 | 0.77 | 2.43% | 31.64 | 32.69 | 30.12 |
| Mar 1, 2023 | 32.04 | 0.62 | 1.97% | 31.42 | 32.12 | 30.83 |
Kymera Therapeutics, Inc. Events
| Čas (UTC) (UTC) | Država | Dogodek |
|---|---|---|
| No events scheduled | ||
- Letni
- Četrtletno
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Skupni prihodki | 46.826 | 72.832 | 34.034 | 2.934 | 0 |
| Prihodki | 46.826 | 72.832 | 34.034 | 2.934 | 0 |
| Celotni odhodki iz poslovanja | 208.082 | 173.362 | 80.338 | 45.139 | 21.451 |
| Celotna prodaja/splošni/upravni stroški Odhodki | 43.834 | 36.345 | 18.233 | 7.981 | 3.772 |
| Raziskave in razvoj | 164.248 | 137.017 | 62.105 | 37.158 | 17.679 |
| Prihodki iz poslovanja | -161.256 | -100.53 | -46.304 | -42.205 | -21.451 |
| Prihodki (odhodki) od obresti, neto Neoperativni | 6.448 | 0.313 | 0.711 | 0.959 | -0.016 |
| Čisti dobiček pred obdavčitvijo | -154.808 | -100.217 | -45.593 | -41.246 | -21.467 |
| Čisti dobiček po davkih | -154.808 | -100.217 | -45.593 | -41.246 | -21.467 |
| Čisti dobiček pred dodatnimi postavkami | -154.808 | -100.217 | -45.593 | -41.246 | -21.467 |
| Čisti dobiček | -154.808 | -100.217 | -45.593 | -41.246 | -21.467 |
| Prihodek, ki je na razpolago navadnim delničarjem, brez dodatnih postavk | -154.808 | -100.217 | -54.643 | -41.246 | -21.467 |
| Prihodek, ki je na razpolago skupnemu dobičku, vključno z dodatnimi postavkami | -154.808 | -100.217 | -54.643 | -41.246 | -21.467 |
| Popravljen čisti dobiček | -154.808 | -100.217 | -54.643 | -41.246 | -21.467 |
| Popravljene ponderirane povprečne delnice | 53.9332 | 47.989 | 44.4822 | 43.1386 | 43.1386 |
| Popravljen dobiček na delnico brez upoštevanja izrednih postavk | -2.87036 | -2.08833 | -1.22842 | -0.95613 | -0.49763 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | ||
| Popravljen normalizirani dobiček na enoto čistega dobička | -2.87036 | -2.08833 | -1.22842 | -0.95613 | -0.49763 |
| Total Adjustments to Net Income | 0 | -9.05 |
| Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | |
|---|---|---|---|---|---|
| Skupni prihodki | 16.139 | 9.551 | 11.514 | 9.622 | 15.275 |
| Prihodki | 16.139 | 9.551 | 11.514 | 9.622 | 15.275 |
| Celotni odhodki iz poslovanja | 54.769 | 54.433 | 52.324 | 46.555 | 49.269 |
| Celotna prodaja/splošni/upravni stroški Odhodki | 11.636 | 10.556 | 11.031 | 10.611 | 11.74 |
| Raziskave in razvoj | 43.133 | 43.877 | 41.293 | 35.944 | 37.529 |
| Prihodki iz poslovanja | -38.63 | -44.882 | -40.81 | -36.933 | -33.994 |
| Prihodki (odhodki) od obresti, neto Neoperativni | 3.765 | 1.88 | 0.553 | 0.249 | 0.094 |
| Čisti dobiček pred obdavčitvijo | -34.865 | -43.002 | -40.257 | -36.684 | -33.9 |
| Čisti dobiček po davkih | -34.865 | -43.002 | -40.257 | -36.684 | -33.9 |
| Čisti dobiček pred dodatnimi postavkami | -34.865 | -43.002 | -40.257 | -36.684 | -33.9 |
| Čisti dobiček | -34.865 | -43.002 | -40.257 | -36.684 | -33.9 |
| Total Adjustments to Net Income | 0 | ||||
| Prihodek, ki je na razpolago navadnim delničarjem, brez dodatnih postavk | -34.865 | -43.002 | -40.257 | -36.684 | -33.9 |
| Prihodek, ki je na razpolago skupnemu dobičku, vključno z dodatnimi postavkami | -34.865 | -43.002 | -40.257 | -36.684 | -33.9 |
| Popravljen čisti dobiček | -34.865 | -43.002 | -40.257 | -36.684 | -33.9 |
| Popravljene ponderirane povprečne delnice | 57.9326 | 54.5355 | 51.7724 | 51.6511 | 51.4312 |
| Popravljen dobiček na delnico brez upoštevanja izrednih postavk | -0.60182 | -0.78851 | -0.77758 | -0.71023 | -0.65913 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | ||
| Popravljen normalizirani dobiček na enoto čistega dobička | -0.60182 | -0.78851 | -0.77758 | -0.71023 | -0.65913 |
- Letni
- Četrtletno
| 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|
| Kratkoročna sredstva skupaj | 451.273 | 302.339 | 92.845 | 41.79 |
| Denarna sredstva in kratkoročne naložbe | 442.418 | 296.202 | 91.957 | 41.26 |
| Denarna sredstva in ustrezniki | 47.976 | 31.004 | 76.015 | 41.26 |
| Kratkoročne naložbe | 394.442 | 265.198 | 15.942 | 0 |
| Celotne terjatve, neto | 0.135 | 1.433 | 0 | 0.148 |
| Prepaid Expenses | 8.72 | 4.704 | 0.888 | 0.382 |
| Total Assets | 605.905 | 487.175 | 116.702 | 44.231 |
| Property/Plant/Equipment, Total - Net | 21.307 | 20.686 | 22.083 | 2.242 |
| Property/Plant/Equipment, Total - Gross | 25.223 | 22.833 | 23.132 | 2.466 |
| Accumulated Depreciation, Total | -3.916 | -2.147 | -1.049 | -0.224 |
| Other Long Term Assets, Total | 8.138 | 1.619 | 1.774 | 0.199 |
| Total Current Liabilities | 92.542 | 110.617 | 34.57 | 4.687 |
| Accounts Payable | 4.005 | 4.368 | 3.276 | 2.056 |
| Accrued Expenses | 25.08 | 12.896 | 7.175 | 2.225 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 1.138 | 0.689 | 0.681 | 0.302 |
| Other Current Liabilities, Total | 62.319 | 92.664 | 23.438 | 0.104 |
| Total Liabilities | 146.267 | 203.287 | 82.028 | 5.238 |
| Total Long Term Debt | 1.14 | 0.604 | 1.165 | 0.393 |
| Capital Lease Obligations | 1.14 | 0.604 | 1.165 | 0.393 |
| Other Liabilities, Total | 52.585 | 92.066 | 46.293 | 0.158 |
| Total Equity | 459.638 | 283.888 | 34.674 | 38.993 |
| Redeemable Preferred Stock | 109.08 | 73.429 | ||
| Common Stock | 0.005 | 0.004 | 0 | 0 |
| Additional Paid-In Capital | 689.275 | 412.777 | 2.044 | 0.774 |
| Retained Earnings (Accumulated Deficit) | -228.982 | -128.765 | -76.456 | -35.21 |
| Other Equity, Total | -0.66 | -0.128 | 0.006 | 0 |
| Total Liabilities & Shareholders’ Equity | 605.905 | 487.175 | 116.702 | 44.231 |
| Total Common Shares Outstanding | 51.5362 | 44.4822 | 43.1386 | 43.1386 |
| Accounts Receivable - Trade, Net | 0.135 | 0.856 | ||
| Long Term Investments | 125.187 | 162.531 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Kratkoročna sredstva skupaj | 431.382 | 451.273 | 543.731 | 364.806 | 340.791 |
| Denarna sredstva in kratkoročne naložbe | 420.812 | 442.418 | 536.386 | 359.107 | 333.537 |
| Denarna sredstva in ustrezniki | 33.733 | 47.976 | 156.819 | 84.903 | 53.098 |
| Kratkoročne naložbe | 387.079 | 394.442 | 379.567 | 274.204 | 280.439 |
| Celotne terjatve, neto | 1.263 | 0.135 | 1.573 | 0.904 | 1.734 |
| Accounts Receivable - Trade, Net | 1.263 | 0.135 | 1.573 | 0.904 | 0.878 |
| Prepaid Expenses | 9.307 | 8.72 | 5.772 | 4.795 | 5.52 |
| Total Assets | 563.06 | 605.905 | 642.453 | 434.386 | 464.552 |
| Property/Plant/Equipment, Total - Net | 21.066 | 21.307 | 21.724 | 21.766 | 20.502 |
| Property/Plant/Equipment, Total - Gross | 25.668 | 25.223 | 24.951 | 24.942 | 23.127 |
| Accumulated Depreciation, Total | -4.602 | -3.916 | -3.227 | -3.176 | -2.625 |
| Long Term Investments | 102.478 | 125.187 | 74.692 | 45.305 | 101.639 |
| Other Long Term Assets, Total | 8.134 | 8.138 | 2.306 | 2.509 | 1.62 |
| Total Current Liabilities | 88.339 | 92.542 | 94.493 | 108.685 | 110.137 |
| Accounts Payable | 2.567 | 4.005 | 5.033 | 8.177 | 8.348 |
| Accrued Expenses | 22.913 | 25.08 | 21.105 | 16.838 | 12.962 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 1.087 | 1.138 | 1.189 | 1.038 | 0.64 |
| Other Current Liabilities, Total | 61.772 | 62.319 | 67.166 | 82.632 | 88.187 |
| Total Liabilities | 134.34 | 146.267 | 159.318 | 176.282 | 189.305 |
| Total Long Term Debt | 0.927 | 1.14 | 1.347 | 1.145 | 0.498 |
| Capital Lease Obligations | 0.927 | 1.14 | 1.347 | 1.145 | 0.498 |
| Other Liabilities, Total | 45.074 | 52.585 | 63.478 | 66.452 | 78.67 |
| Total Equity | 428.72 | 459.638 | 483.135 | 258.104 | 275.247 |
| Common Stock | 0.005 | 0.005 | 0.005 | 0.005 | 0.004 |
| Additional Paid-In Capital | 697.597 | 689.275 | 678.358 | 424.599 | 417.096 |
| Retained Earnings (Accumulated Deficit) | -265.666 | -228.982 | -195.082 | -166.5 | -141.84 |
| Other Equity, Total | -3.216 | -0.66 | -0.146 | 0 | -0.013 |
| Total Liabilities & Shareholders’ Equity | 563.06 | 605.905 | 642.453 | 434.386 | 464.552 |
| Total Common Shares Outstanding | 51.6927 | 51.5362 | 51.2565 | 45.3277 | 44.8794 |
- Letni
- Četrtletno
| 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|
| Čisti prihodki/začetna postavka | -100.217 | -45.593 | -41.246 | -21.467 |
| Denarna sredstva iz poslovanja | -128.946 | 88.13 | 17.905 | -17.863 |
| Denarna sredstva iz poslovanja | 2.397 | 1.763 | 0.825 | 0.205 |
| Nedenarne postavke | 30.797 | 7.093 | 1.639 | 1.091 |
| Denarna sredstva Plačane obresti | 0.158 | 0.115 | 0.046 | 0.015 |
| Spremembe v obratnem kapitalu | -61.923 | 124.867 | 56.687 | 2.308 |
| Denarna sredstva pri naložbenju | -99.835 | -422.588 | -16.486 | -1.356 |
| Kapitalski izdatki | -1.597 | -9.096 | -0.532 | -1.356 |
| Celotne druge postavke denarnih tokov pri naložbenju | -98.238 | -413.492 | -15.954 | 0 |
| Denarna sredstva pri financiranju | 250.28 | 289.262 | 34.911 | 52.932 |
| Izdaja (odplačilo) delnic, neto | 249.18 | 276.289 | 35.282 | 53.227 |
| Izdaja (odplačilo) dolga, neto | -0.849 | -0.554 | -0.371 | -0.295 |
| Neto sprememba denarnih sredstev | 21.499 | -45.196 | 36.33 | 33.713 |
| Postavke denarnega toka pri financiranju | 1.949 | 13.527 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -36.684 | -100.217 | -66.317 | -37.735 | -13.075 |
| Cash From Operating Activities | -40.295 | -128.946 | -90.594 | -53.334 | -22.823 |
| Cash From Operating Activities | 0.687 | 2.397 | 1.708 | 1.037 | 0.485 |
| Non-Cash Items | 9.048 | 30.797 | 20.483 | 11.409 | 4.451 |
| Cash Interest Paid | 0.046 | 0.158 | 0.106 | 0.054 | 0.024 |
| Changes in Working Capital | -13.346 | -61.923 | -46.468 | -28.045 | -14.684 |
| Cash From Investing Activities | 25.863 | -99.835 | -31.816 | 105.046 | 44.323 |
| Capital Expenditures | -0.482 | -1.597 | -1.096 | -0.79 | -0.164 |
| Other Investing Cash Flow Items, Total | 26.345 | -98.238 | -30.72 | 105.836 | 44.487 |
| Cash From Financing Activities | 0.185 | 250.28 | 248.226 | 2.187 | 0.595 |
| Financing Cash Flow Items | 0 | 1.949 | 1.95 | -0.397 | -0.397 |
| Issuance (Retirement) of Stock, Net | 0.449 | 249.18 | 246.969 | 2.925 | 1.147 |
| Issuance (Retirement) of Debt, Net | -0.264 | -0.849 | -0.693 | -0.341 | -0.155 |
| Net Change in Cash | -14.247 | 21.499 | 125.816 | 53.899 | 22.095 |
| Ime vlagatelja | Vrsta vlagatelja | Odstotek neporavnanih obveznosti | Delnice v lasti | Sprememba delnic | Datum imetništva | Ocena prometa |
|---|---|---|---|---|---|---|
| Atlas Venture | Venture Capital | 10.6159 | 5858262 | -126474 | 2023-01-12 | LOW |
| BVF Partners L.P. | Hedge Fund | 8.5779 | 4733611 | 41007 | 2023-01-12 | LOW |
| Wellington Management Company, LLP | Investment Advisor/Hedge Fund | 8.3197 | 4591089 | 1180703 | 2022-12-31 | LOW |
| T. Rowe Price Associates, Inc. | Investment Advisor | 7.8899 | 4353945 | 277562 | 2022-12-31 | LOW |
| Avoro Capital Advisors LLC | Investment Advisor/Hedge Fund | 6.9767 | 3850000 | 1680770 | 2022-12-31 | LOW |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 6.619 | 3652608 | 797130 | 2022-12-31 | LOW |
| Vertex Pharmaceuticals Inc | Corporation | 5.8007 | 3201049 | 49928 | 2022-03-31 | |
| Baker Bros. Advisors LP | Hedge Fund | 5.2186 | 2879825 | 0 | 2022-12-31 | LOW |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 5.1577 | 2846221 | 160817 | 2022-12-31 | LOW |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 5.1454 | 2839421 | 172415 | 2022-12-31 | LOW |
| Redmile Group, LLC | Investment Advisor/Hedge Fund | 4.8453 | 2673837 | -202800 | 2022-12-31 | LOW |
| Invus Public Equities Advisors, LLC | Investment Advisor | 3.6243 | 2000000 | 500000 | 2022-12-31 | LOW |
| T. Rowe Price Investment Management, Inc. | Investment Advisor | 3.5445 | 1955977 | -40552 | 2022-12-31 | MED |
| Rock Springs Capital Management LP | Hedge Fund | 2.2249 | 1227779 | 181036 | 2022-12-31 | LOW |
| Fidelity Management & Research Company LLC | Investment Advisor | 1.5331 | 846046 | 520360 | 2022-12-31 | LOW |
| Wasatch Global Investors Inc | Investment Advisor/Hedge Fund | 1.5081 | 832221 | -228340 | 2022-12-31 | LOW |
| EcoR1 Capital, LLC | Hedge Fund | 1.4426 | 796093 | 0 | 2022-12-31 | LOW |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.3538 | 747071 | 45849 | 2022-12-31 | LOW |
| Mellon Investments Corporation | Investment Advisor/Hedge Fund | 1.2316 | 679621 | -41254 | 2022-12-31 | LOW |
| Aquilo Capital Management, LLC | Investment Advisor/Hedge Fund | 1.1406 | 629411 | 299165 | 2022-12-31 | LOW |
Zakaj izbrati Capital.com? Številke govorijo same zase.
Capital.com Group500K+
Borzni posredniki
92K+
Aktivne stranke mesečno
$53M+
Mesečni obseg naložb
$30M+
Dvigi vsak mesec
Kalkulator trgovanja
Izračunajte svoj hipotetični P&L, če bi trgovino s CFD odprli na določen datum (izberite datum) in jo zaprli na drug datum (izberite datum).
Trgovalna provizija
0
- 1:1
Vzvod
1:1
- 20
- 100
- 500
- 1000
- 10000
Naložbe
Velikost posla (finančni vzvod x naložba):
Odpiranje
Zapiranje
Kratka Dolga
Kymera Therapeutics, Inc. Company profile
O družbi Kymera Therapeutics, Inc.
Kymera Therapeutics, Inc. je biofarmacevtsko podjetje. Podjetje se osredotoča na odkrivanje in razvoj terapij z majhnimi molekulami, ki selektivno razgrajujejo beljakovine, ki povzročajo bolezni, z izkoriščanjem telesu lastnega naravnega sistema za razgradnjo beljakovin. Njegova platforma za ciljano razgradnjo beljakovin (TPD) Pegasus mu omogoča odkrivanje selektivnih malih molekul za razgradnjo beljakovin, ki delujejo na beljakovine, ki povzročajo bolezni v telesu. Platforma Pegasus podjetja vključuje E3 Ligase Whole-Body Atlas, E3 Ligase Binders Toolbox, Ternary Complex Modeling, Quantitative System Pharmacology Model in Chemistry. Njeni programi v klinični fazi vključujejo IRAK4, IRAKIMiD in STAT3, ki obravnavajo tarče znotraj interlevkin-1 receptorja/tollu podobnega receptorja (IL-1R/TLR) in janus kinaze/signalnih prenašalcev in aktivatorjev transkripcije (JAK/STAT). Njegovi programi se osredotočajo na zdravljenje številnih imunsko-vnetnih bolezni, hematoloških malignomov in solidnih tumorjev.
| Industry: | Biotechnology & Medical Research (NEC) |
200 Arsenal Yards Blvd., Suite 230
2Nd Floor
02472
Izkaz poslovnega izida
- Annual
- Quarterly
Ljudje gledajo tudi
Še vedno iščete posrednika, ki mu lahko zaupate?
Pridružite se 500.000+ trgovcem po vsem svetu, ki so se odločili za trgovanje s Capital.com